Esepapogene zalarnarepvec is under clinical development by Hookipa Pharma and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC). According to GlobalData, Phase II drugs for Head And Neck Squamous Cell Carcinoma (HNSC) have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Esepapogene zalarnarepvec’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Esepapogene zalarnarepvec overview

Esepapogene zalarnarepvec (HB-201, TheraT) is under development for the prevention of human papillomavirus 16 (HPV 16) driven oropharynx cancer, metastatic squamous cell carcinoma, cervical cancer, head and neck cancer squamous cell carcinoma and melanoma. The vaccine candidate is administered by intratumor and intravenous routes. It is developed based on TheraT platform which generates replication attenuated viral vectors expressing gene of interest. The vaccine candidate acts by targeting human papillomavirus protein E6 and E7.

It was also under development for anal cancer, penile cancer, vaginal, vulvar cancer and cervical cancer.

Hookipa Pharma overview

Hookipa Pharma (Hookipa) is a clinical-stage biopharmaceutical company that develops novel immunotherapies through its arenavirus platform for cancer and chronic infectious diseases using its replicating technology and non-replicating technology. Its pipeline products include HB-200 for the treatment of human papillomavirus 16-positive (HPV16+) cancers; HB-700 for the treatment of Kristen rat sarcoma viral oncogene homolog (KRAS) mutated cancers; HB-300 for the treatment of prostate cancer; HB-400 for hepatitis B (HBV) treatment; and HB-500 for the human immunodeficiency virus (HIV) treatment. Hookipa works in collaboration with other pharmaceutical companies for the development of immunotherapies. Hookipa is headquartered in New York, the US.

For a complete picture of Esepapogene zalarnarepvec’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.